Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000895345-25-000001
Filing Date
2025-01-02
Accepted
2025-01-02 07:07:07
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10048
  Complete submission text file 0000895345-25-000001.txt   11796
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Subject) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92241 | Film No.: 25500211
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 11682 EL CAMINO REAL, SUITE 320 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 320 SAN DIEGO CA 92130 (858) 400-3115
BCTG Holdings, LLC (Filed by) CIK: 0001823427 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13D/A